Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations

Itanet (Italian Association for Neuroendocrine Tumours)

Research output: Contribution to journalArticle

Abstract

Background: Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. Aim: To compare the prognostic role of tumour burden in PanNENs and GI NENs. Patients and methods: This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume (<25% or >25%). Overall survival as assessed by Kaplan-Meier curves, and Cox proportional hazards method was used to perform risk factor analysis. Results: The analysis included 300 patients, including 166 panNENs (55.3%) and 134 GI NENs (44.7%). A total of 158 patients (52.7%) had G2 tumours, 107 had G1 tumours (35.7%), and 35 had G3 tumours (11.6%). Tumour liver involvement >25% was observed in 187 patients (62.3%): 106 PanNENs (56.7%), and 81 GI NENs (43.3%) (p = 0.551). Bone metastases were present in 45 patients (15%): 22 PanNENs (13.2%) and 23 GI NENs (17.1%) (p = 0.416). Characteristics of the PanNENs, including: grading (G2 vs G1, HR = 3.7; G3 vs G1, HR = 16.40), liver involvement > 25% (HR = 3.09), and bone metastases (HR = 2.27) were independent predictors for poor survival, whereas the only significant risk factor in GI NENs was grading (G2 vs G1, HR = 4.36; G3 vs G1, HR = 8.60). Conclusions: PanNENs and GI NENs have different risk profiles. Liver tumour volume and the presence of bone metastases significantly affect survival in patients with PanNENs but has no impact on the clinical outcomes of GI NENs.

Original languageEnglish
JournalPancreatology
DOIs
Publication statusPublished - 2019

Fingerprint

Tumor Burden
Neoplasms
Liver
Neoplasm Metastasis
Bone and Bones
Survival
Statistical Factor Analysis

Keywords

  • Bone metastases
  • Grading
  • Ki67
  • Metastases
  • Neuroendocrine tumours
  • Pancreatic endocrine tumours
  • Prognosis
  • Tumour burden

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia : A comparison between pancreatic and gastrointestinal localizations. / Itanet (Italian Association for Neuroendocrine Tumours).

In: Pancreatology, 2019.

Research output: Contribution to journalArticle

@article{0537e41424104b3391320986a83b6bb5,
title = "Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations",
abstract = "Background: Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. Aim: To compare the prognostic role of tumour burden in PanNENs and GI NENs. Patients and methods: This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume (<25{\%} or >25{\%}). Overall survival as assessed by Kaplan-Meier curves, and Cox proportional hazards method was used to perform risk factor analysis. Results: The analysis included 300 patients, including 166 panNENs (55.3{\%}) and 134 GI NENs (44.7{\%}). A total of 158 patients (52.7{\%}) had G2 tumours, 107 had G1 tumours (35.7{\%}), and 35 had G3 tumours (11.6{\%}). Tumour liver involvement >25{\%} was observed in 187 patients (62.3{\%}): 106 PanNENs (56.7{\%}), and 81 GI NENs (43.3{\%}) (p = 0.551). Bone metastases were present in 45 patients (15{\%}): 22 PanNENs (13.2{\%}) and 23 GI NENs (17.1{\%}) (p = 0.416). Characteristics of the PanNENs, including: grading (G2 vs G1, HR = 3.7; G3 vs G1, HR = 16.40), liver involvement > 25{\%} (HR = 3.09), and bone metastases (HR = 2.27) were independent predictors for poor survival, whereas the only significant risk factor in GI NENs was grading (G2 vs G1, HR = 4.36; G3 vs G1, HR = 8.60). Conclusions: PanNENs and GI NENs have different risk profiles. Liver tumour volume and the presence of bone metastases significantly affect survival in patients with PanNENs but has no impact on the clinical outcomes of GI NENs.",
keywords = "Bone metastases, Grading, Ki67, Metastases, Neuroendocrine tumours, Pancreatic endocrine tumours, Prognosis, Tumour burden",
author = "{Itanet (Italian Association for Neuroendocrine Tumours)} and Francesco Panzuto and Sara Puscedddu and Antongiulio Faggiano and Maria Rinzivillo and Nicole Brighi and Natalie Prinzi and Ferdinando Riccardi and Elsa Iannicelli and Ilaria Maggio and Daniela Femia and Salvatore Tafuto and Lisa Manuzzi and {Di Sarno}, Antonella and Bruno Annibale and {de Braud}, Filippo and Davide Campana",
year = "2019",
doi = "10.1016/j.pan.2019.09.015",
language = "English",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia

T2 - A comparison between pancreatic and gastrointestinal localizations

AU - Itanet (Italian Association for Neuroendocrine Tumours)

AU - Panzuto, Francesco

AU - Puscedddu, Sara

AU - Faggiano, Antongiulio

AU - Rinzivillo, Maria

AU - Brighi, Nicole

AU - Prinzi, Natalie

AU - Riccardi, Ferdinando

AU - Iannicelli, Elsa

AU - Maggio, Ilaria

AU - Femia, Daniela

AU - Tafuto, Salvatore

AU - Manuzzi, Lisa

AU - Di Sarno, Antonella

AU - Annibale, Bruno

AU - de Braud, Filippo

AU - Campana, Davide

PY - 2019

Y1 - 2019

N2 - Background: Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. Aim: To compare the prognostic role of tumour burden in PanNENs and GI NENs. Patients and methods: This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume (<25% or >25%). Overall survival as assessed by Kaplan-Meier curves, and Cox proportional hazards method was used to perform risk factor analysis. Results: The analysis included 300 patients, including 166 panNENs (55.3%) and 134 GI NENs (44.7%). A total of 158 patients (52.7%) had G2 tumours, 107 had G1 tumours (35.7%), and 35 had G3 tumours (11.6%). Tumour liver involvement >25% was observed in 187 patients (62.3%): 106 PanNENs (56.7%), and 81 GI NENs (43.3%) (p = 0.551). Bone metastases were present in 45 patients (15%): 22 PanNENs (13.2%) and 23 GI NENs (17.1%) (p = 0.416). Characteristics of the PanNENs, including: grading (G2 vs G1, HR = 3.7; G3 vs G1, HR = 16.40), liver involvement > 25% (HR = 3.09), and bone metastases (HR = 2.27) were independent predictors for poor survival, whereas the only significant risk factor in GI NENs was grading (G2 vs G1, HR = 4.36; G3 vs G1, HR = 8.60). Conclusions: PanNENs and GI NENs have different risk profiles. Liver tumour volume and the presence of bone metastases significantly affect survival in patients with PanNENs but has no impact on the clinical outcomes of GI NENs.

AB - Background: Although prognosis of NENs is affected by several features including tumour burden, the specific role of this factor in pancreatic NENs (PanNENs) and gastrointestinal NENs (GI NENs) is not well established. Aim: To compare the prognostic role of tumour burden in PanNENs and GI NENs. Patients and methods: This study was a retrospective analysis of stage IV PanNENs and GI NENs. Tumours were classified based on liver tumour volume (<25% or >25%). Overall survival as assessed by Kaplan-Meier curves, and Cox proportional hazards method was used to perform risk factor analysis. Results: The analysis included 300 patients, including 166 panNENs (55.3%) and 134 GI NENs (44.7%). A total of 158 patients (52.7%) had G2 tumours, 107 had G1 tumours (35.7%), and 35 had G3 tumours (11.6%). Tumour liver involvement >25% was observed in 187 patients (62.3%): 106 PanNENs (56.7%), and 81 GI NENs (43.3%) (p = 0.551). Bone metastases were present in 45 patients (15%): 22 PanNENs (13.2%) and 23 GI NENs (17.1%) (p = 0.416). Characteristics of the PanNENs, including: grading (G2 vs G1, HR = 3.7; G3 vs G1, HR = 16.40), liver involvement > 25% (HR = 3.09), and bone metastases (HR = 2.27) were independent predictors for poor survival, whereas the only significant risk factor in GI NENs was grading (G2 vs G1, HR = 4.36; G3 vs G1, HR = 8.60). Conclusions: PanNENs and GI NENs have different risk profiles. Liver tumour volume and the presence of bone metastases significantly affect survival in patients with PanNENs but has no impact on the clinical outcomes of GI NENs.

KW - Bone metastases

KW - Grading

KW - Ki67

KW - Metastases

KW - Neuroendocrine tumours

KW - Pancreatic endocrine tumours

KW - Prognosis

KW - Tumour burden

UR - http://www.scopus.com/inward/record.url?scp=85072781959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072781959&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2019.09.015

DO - 10.1016/j.pan.2019.09.015

M3 - Article

AN - SCOPUS:85072781959

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

ER -